Diabetes, Obesity and Metabolism logo Wiley-Blackwell logo

Publisher: Wiley-Blackwell

Related content
Volume 14, Number 1, 1 January 2012

< previous issue | all issues | next issue >

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
pp. 5-14(10)
Authors: DeFronzo, R. A.; Davidson, J. A.; Del Prato, S.

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
pp. 15-22(8)
Authors: Dobbins, R. L.; O’Connor‐Semmes, R.; Kapur, A.; Kapitza, C.; Golor, G.; Mikoshiba, I.; Tao, W.; Hussey, E. K.

Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients
pp. 23-29(7)
Authors: Bo, S.; Ciccone, G.; Rosato, R.; Villois, P.; Appendino, G.; Ghigo, E.; Grassi, G.

Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk
pp. 30-39(10)
Authors: Stalenhoef, A. F. H.; Davidson, M. H.; Robinson, J. G.; Burgess, T.; Duttlinger‐Maddux, R.; Kallend, D.; Goldberg, A. C.; Bays, H.

Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus
pp. 40-46(7)
Authors: Henry, R. R.; Aroda, V. R.; Mudaliar, S.; Garvey, W. T.; Chou, H. S.; Jones, M. R.

Oestrogen alters adipocyte biology and protects female mice from adipocyte inflammation and insulin resistance
pp. 58-66(9)
Authors: Stubbins, R. E.; Najjar, K.; Holcomb, V. B.; Hong, J.; Núñez, N. P.

Effect of initial combination therapy with sitagliptin and metformin on β‐cell function in patients with type 2 diabetes
pp. 67-76(10)
Authors: Williams‐Herman, D.; Xu, L.; Teng, R.; Golm, G. T.; Johnson, J.; Davies, M. J.; Kaufman, K. D.; Goldstein, B. J.

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
pp. 83-90(8)
Authors: Grempler, R.; Thomas, L.; Eckhardt, M.; Himmelsbach, F.; Sauer, A.; Sharp, D. E.; Bakker, R. A.; Mark, M.; Klein, T.; Eickelmann, P.

Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
pp. 94-96(3)
Authors: Thomas, L.; Grempler, R.; Eckhardt, M.; Himmelsbach, F.; Sauer, A.; Klein, T.; Eickelmann, P.; Mark, M.

News and Views
pp. 97-99(3)
Author: Idris, Iskandar

< previous issue | all issues | next issue >


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page